This page shows the latest Sun Pharma news and features for those working in and with pharma, biotech and healthcare.
As the world’s second-largest healthcare market after the US, China has been a target for many big pharma companies, and AstraZeneca is already among the multinational drug industry’s ... At the same time, AZ has just announced a partnership with
Adds to China's growing presence in life sciences. Shares in newly-listed Chinese drugmaker Hansoh Pharma have risen sharply on their debut in Hong Kong, propelling its founder Zhong Huijuan ... Hansoh was set up in 2015 by Zhong, a former chemistry
Stelara has since been joined by J&J’s follow-up IL-23 inhibitor Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie/Boehringer Ingelheim’s Skyrizi (risankizumab), which are all
including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.
The drug was originally developed by India’s Sun Pharma and is licensed to Merck &Co in the US, where it was approved in March. ... Kigabeq (vigabatrin), the other PUMA medicine, has been developed by Orphelia Pharma for infantile spasms (West's
Ilumya isn’t entirely home-grown, as Sun Pharma licensed the interleukin-23 (IL-23) inhibitor for Merck &Co/MSD in 2014, but the green light is a landmark along the ... With the approval of Ilumya and our long-standing commitment in dermatology, we are
More from news
Approximately 6 fully matching, plus 43 partially matching documents found.
295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Sun Pharma. 3.5%. BSN Medical. Svenska Cellulosa. -0.7%. Claris. Baxter. -1.3%.
Sun Pharma will also assume Biosintez's $36m debt as part of this transaction. ... acquisition - company. 78. JSC Biosintez/ Sun Pharma. Russian pharma focusing on hospital segment with 2015 revenues of approx $52m.
to, for example, Sun Pharma and vice-versa.
In at numbers 2, 3 and 4 are the LEO-AstraZeneca deal with an upfront of $115m, Astellas-Cytokinetics at $95m and Almirall-Sun Pharma at $50m (see below). ... Almirall paid $50m upfront to Sun Pharma for a licence to tildrakizumab (an IL-23p19 antibody)
This may not be as simple as it seems. Last year the FDA imposed export bans from 20 or so plants in India and warned several others, and whilst Sun Pharma ... Doctors have shied away from Ranbaxy brands in recent years and it is rumoured that a solution
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Emma Morton appointed media strategist at PR firm. Emma Morton, health and science editor at UK newspaper The Sun, is to join the London healthcare team of communications firm Ruder Fin ... Morton spent 13 years at The Sun, initially joining as a
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Michael Milane, MD, MBA DUSA Pharmaceuticals, a SUN Pharma company . Executive Director of Medical Affairs Jennifer Williams, PhD, JD, MBA, MS, RN Bard Medical Director of Medical Science Liaisons.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...